|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
ELV058267654 |
003 |
DE-627 |
005 |
20230625004749.0 |
007 |
cr uuu---uuuuu |
008 |
220808s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.earlhumdev.2022.105598
|2 doi
|
028 |
5 |
2 |
|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001821.pica
|
035 |
|
|
|a (DE-627)ELV058267654
|
035 |
|
|
|a (ELSEVIER)S0378-3782(22)00061-5
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
082 |
0 |
4 |
|a 610
|q VZ
|
082 |
0 |
4 |
|a 610
|q VZ
|
084 |
|
|
|a 44.45
|2 bkl
|
100 |
1 |
|
|a Sawano, Toru
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Lung to thorax transverse area ratio as a predictor of neurodevelopmental outcomes in fetuses with congenital diaphragmatic hernia
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
520 |
|
|
|a Infants with congenital diaphragmatic hernia (CDH) are at risk of neurodevelopmental disabilities. This study aimed to investigate the association between lung to thorax transverse area ratio (LTR) and neurodevelopmental outcomes at 3 years of age in fetuses with CDH.
|
700 |
1 |
|
|a Kondo, Takuya
|4 oth
|
700 |
1 |
|
|a Ebihara, Go
|4 oth
|
700 |
1 |
|
|a Nagata, Kouji
|4 oth
|
700 |
1 |
|
|a Inoue, Hirosuke
|4 oth
|
700 |
1 |
|
|a Fujiyoshi, Junko
|4 oth
|
700 |
1 |
|
|a Ochiai, Masayuki
|4 oth
|
700 |
1 |
|
|a Kido, Saki
|4 oth
|
700 |
1 |
|
|a Fujita, Yasuyuki
|4 oth
|
700 |
1 |
|
|a Sakai, Yasunari
|4 oth
|
700 |
1 |
|
|a Kato, Kiyoko
|4 oth
|
700 |
1 |
|
|a Tajiri, Tatsuro
|4 oth
|
700 |
1 |
|
|a Ohga, Shouichi
|4 oth
|
773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
773 |
1 |
8 |
|g volume:170
|g year:2022
|g pages:0
|
856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2022.105598
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_U
|
912 |
|
|
|a GBV_ELV
|
912 |
|
|
|a SYSFLAG_U
|
912 |
|
|
|a SSG-OLC-PHA
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_350
|
936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
951 |
|
|
|a AR
|
952 |
|
|
|d 170
|j 2022
|h 0
|